10 hours ago
Sept 15, 2026, 2:38 pm EDT
For months, investors and banking industry executives have privately speculated Wells Fargo could be poised to acquire a smaller lender.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Insurers like Humana are canceling some Medicare Advantage plans. How to make the best of it.
#sept #wells #reserved #humana
For months, investors and banking industry executives have privately speculated Wells Fargo could be poised to acquire a smaller lender.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Insurers like Humana are canceling some Medicare Advantage plans. How to make the best of it.
#sept #wells #reserved #humana
6 days ago
On August 11, Humana Inc. (NYSE:HUM) announced that its Medicaid plan, Humana Healthy Horizons in Indiana, is collaborating with HealthStream, Inc. (NASDAQ:HSTM). The partnership expands access to workforce training for caregivers, aiming to recruit and retain talent in rural and underserved communities. While one provides healthcare coverage and the other builds the software to train healthcare workers, both companies are capitalizing on the industry's critical focus: solving caregiving shortages and optimizing healthcare delivery.
HealthStream emerges as the operationally cleaner, higher-growth performer, while Humana continues to navigate a more complex transition marked by regulatory and profitability pressures. Humana Inc. (NYSE:HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, with an Insurance segment GAAP benefit ratio of 91.2%. The company reaffirmed its full-year adjusted EPS guidance of at least $9.00 but lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36, reflecting non-cash adjustments and value creation charges. Although individual Medicare Advantage membership is expected to grow approximately 25% in 2026, lower Star Ratings remain a significant drag on profitability.
HealthStream, Inc. (NASDAQ:HSTM), meanwhile, delivered record Q2 2026 results, with revenue rising 12.5% year over year to $83.7 million. Operating income increased 41.4% to $8.3 million, while net income climbed 23.8% to $6.7 million, or $0.23 per diluted share. Adjusted EBITDA also increased 16.9% to $20.6 million. The company's debt-free balance sheet, supported by $66.7 million in cash and cash equivalents, further strengthens its financial flexibility. While Humana operates at substantially greater scale, HealthStream is demonstrating stronger operational leverage, margin expansion, and balance sheet flexibility.
Humana's bull case is supported by strong Medicare Advantage membership growth, with the company targeting a 25% increase in 2026, alongside strategic expansion of its CenterWell primary care business and state Medicaid footprint, including its recent Illinois win. These initiatives could strengthen its long-term recovery and expand its addressable market. However, the bear case centers on elevated medical benefit ratios, which reached 91.2% in Q2, as well as regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds. These factors could further squeeze margins and weigh on net earnings.
#healthcare #year
HealthStream emerges as the operationally cleaner, higher-growth performer, while Humana continues to navigate a more complex transition marked by regulatory and profitability pressures. Humana Inc. (NYSE:HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, with an Insurance segment GAAP benefit ratio of 91.2%. The company reaffirmed its full-year adjusted EPS guidance of at least $9.00 but lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36, reflecting non-cash adjustments and value creation charges. Although individual Medicare Advantage membership is expected to grow approximately 25% in 2026, lower Star Ratings remain a significant drag on profitability.
HealthStream, Inc. (NASDAQ:HSTM), meanwhile, delivered record Q2 2026 results, with revenue rising 12.5% year over year to $83.7 million. Operating income increased 41.4% to $8.3 million, while net income climbed 23.8% to $6.7 million, or $0.23 per diluted share. Adjusted EBITDA also increased 16.9% to $20.6 million. The company's debt-free balance sheet, supported by $66.7 million in cash and cash equivalents, further strengthens its financial flexibility. While Humana operates at substantially greater scale, HealthStream is demonstrating stronger operational leverage, margin expansion, and balance sheet flexibility.
Humana's bull case is supported by strong Medicare Advantage membership growth, with the company targeting a 25% increase in 2026, alongside strategic expansion of its CenterWell primary care business and state Medicaid footprint, including its recent Illinois win. These initiatives could strengthen its long-term recovery and expand its addressable market. However, the bear case centers on elevated medical benefit ratios, which reached 91.2% in Q2, as well as regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds. These factors could further squeeze margins and weigh on net earnings.
#healthcare #year
12 days ago
Humana (HUM) confirmed 600,000 affected members and UNH projects 1.1 million fewer enrollees as carriers cut lower-rated 2027 Medicare Advantage plans.
A plan termination triggers a rare guaranteed-issue Medigap window, but only for members who are returning to Original Medicare. Those switching to another Advantage plan do not qualify.
Nonrenewal notices arrive October 2, leaving only 66 days before Open Enrollment closes December 7. Members should save the letter and price both coverage paths immediately.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
Somewhere inside the Centers for Medicare & Medicaid Services (CMS) sits the list of Medicare Advantage plans that will stop existing on December 31, 2026. Insurers submitted their 2027 bids in June. Wall Street **** ysts have dissected the implications on earnings calls all summer. The people enrolled in those plans will find out by mail.
#plans #plan #only #medigap
A plan termination triggers a rare guaranteed-issue Medigap window, but only for members who are returning to Original Medicare. Those switching to another Advantage plan do not qualify.
Nonrenewal notices arrive October 2, leaving only 66 days before Open Enrollment closes December 7. Members should save the letter and price both coverage paths immediately.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
Somewhere inside the Centers for Medicare & Medicaid Services (CMS) sits the list of Medicare Advantage plans that will stop existing on December 31, 2026. Insurers submitted their 2027 bids in June. Wall Street **** ysts have dissected the implications on earnings calls all summer. The people enrolled in those plans will find out by mail.
#plans #plan #only #medigap
13 days ago
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment ******* umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH), a diversified healthcare company, contributed 2.5% to the Fund's performance during the quarter. On September 02, 2026, UnitedHealth Group Incorporated (NYSE:UNH) closed at $399.66 per share. Over the past month UnitedHealth Group Incorporated (NYSE:UNH) was down 1.07%, and its shares gained 28.76% over the past 52 weeks. UnitedHealth Group Incorporated (NYSE:UNH) has a market capitalization of $358.73 billion and its stock has traded within a 52-week range of $255.97 - $461.62.
Eagle Capital Management stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its Q2 2026 investor letter:
"Managed care (13% of capital): UnitedHealth Group Incorporated (NYSE:UNH), Humana, Elevance: These managed care companies have significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Even the largest firms are earning poor margins, and some weaker firms are unprofitable. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Al-driven technology projects can both reduce costs and improve service quality. Since returning as CEO at UnitedHealth last year, Stephen Hemsley and the management team have been correcting some of the company's missteps. Recent results provide growing evidence that the turnaround is well on track. We expect EPS growth of 15-20% over the next several years, driven by moderate revenue growth and significantly e
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH), a diversified healthcare company, contributed 2.5% to the Fund's performance during the quarter. On September 02, 2026, UnitedHealth Group Incorporated (NYSE:UNH) closed at $399.66 per share. Over the past month UnitedHealth Group Incorporated (NYSE:UNH) was down 1.07%, and its shares gained 28.76% over the past 52 weeks. UnitedHealth Group Incorporated (NYSE:UNH) has a market capitalization of $358.73 billion and its stock has traded within a 52-week range of $255.97 - $461.62.
Eagle Capital Management stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its Q2 2026 investor letter:
"Managed care (13% of capital): UnitedHealth Group Incorporated (NYSE:UNH), Humana, Elevance: These managed care companies have significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Even the largest firms are earning poor margins, and some weaker firms are unprofitable. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Al-driven technology projects can both reduce costs and improve service quality. Since returning as CEO at UnitedHealth last year, Stephen Hemsley and the management team have been correcting some of the company's missteps. Recent results provide growing evidence that the turnaround is well on track. We expect EPS growth of 15-20% over the next several years, driven by moderate revenue growth and significantly e
13 days ago
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment ***** umptions. Eagle remains a strong believer in AI but prefers constructing a portfolio that can perform across multiple outcomes rather than relying on one forecast. The firm believes current earnings can overstate underlying economics because semiconductor equipment is depreciated over several years, while free cash flow growth remains much weaker. It also expects competition and additional capacity across AI labs, hyperscalers, and semiconductors to eventually create winners and losers. These dynamics are encouraging Eagle to recycle capital toward attractive opportunities outside the most crowded AI trades while maintaining selective exposure to high-quality beneficiaries. The portfolio trades at a 20% market discount with faster expected EPS growth. Please review the Strategy's top five holdings for key selections in 2026.
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On September 02, 2026, Humana Inc. (NYSE:HUM) closed at $400.97 per share. Over the past month, Humana Inc. (NYSE:HUM) returned 9.18%, and its shares gained 28.52% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $48.15 billion with a 52-week trading range between $163.11 and $428.88.
Eagle Capital Management stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Managed care (13% of capital): UnitedHealth Group, Humana Inc. (NYSE:HUM), Elevance: These managed care companies have significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Even the largest firms are earning poor margins, and some weaker firms are unprofitable. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Al-driven technology projects can both reduce costs and improve service quality. Humana is also making good strides, and we expect significantly improved Star ratings for the company later this year. We expect EPS growth of 15-20% over the next several years, driven by moderate revenue growth and significantly expanding margins."
#eagle
In its second-quarter 2026 investor letter, Eagle Capital Management highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On September 02, 2026, Humana Inc. (NYSE:HUM) closed at $400.97 per share. Over the past month, Humana Inc. (NYSE:HUM) returned 9.18%, and its shares gained 28.52% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $48.15 billion with a 52-week trading range between $163.11 and $428.88.
Eagle Capital Management stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Managed care (13% of capital): UnitedHealth Group, Humana Inc. (NYSE:HUM), Elevance: These managed care companies have significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Even the largest firms are earning poor margins, and some weaker firms are unprofitable. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Al-driven technology projects can both reduce costs and improve service quality. Humana is also making good strides, and we expect significantly improved Star ratings for the company later this year. We expect EPS growth of 15-20% over the next several years, driven by moderate revenue growth and significantly expanding margins."
#eagle
17 days ago
Humana is exiting Medicare Advantage plans affecting 600,000 members in 2027, with federally required non-renewal notices dated October 2.
Federal law grants a guaranteed-issue Medigap right when an MA plan exits, barring insurers from rejecting applicants or charging more for pre-existing conditions.
Before accepting any replacement Advantage plan, members should price Medigap Plan G and verify new coverage includes their doctors, drugs, and hospitals.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
A Humana (NYSE: HUM) Medicare Advantage (MA) member could open the mail in early October and discover that coverage ending December 31 will not be back next year. Humana told investors in July that targeted 2027 exits will affect approximately 600,000 members.
#plan #medicare
Federal law grants a guaranteed-issue Medigap right when an MA plan exits, barring insurers from rejecting applicants or charging more for pre-existing conditions.
Before accepting any replacement Advantage plan, members should price Medigap Plan G and verify new coverage includes their doctors, drugs, and hospitals.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
A Humana (NYSE: HUM) Medicare Advantage (MA) member could open the mail in early October and discover that coverage ending December 31 will not be back next year. Humana told investors in July that targeted 2027 exits will affect approximately 600,000 members.
#plan #medicare
1 month ago
Medicare Advantage plans are shrinking.
Last month, Humana (HUM) announced that it will exit some Medicare Advantage plans for next year, forcing more than half a million seniors to find a new health plan.
The reason for the coverage cutback: high costs and slimmer profit margins in certain markets, according to Humana CFO Celeste Mellet.
It's the second year in a row of plan downsizing for Humana. This year, the company exited three states and 194 counties, affecting around 500,000 members. UnitedHealthcare (UNH) also jettisoned Medicare Advantage plans that served more than 600,000 seniors.
According to KFF research, the percentage of Medicare Advantage enrollees who faced terminated plans this year reached 60% or higher in Wyoming, South Dakota, New Hampshire, North Dakota, and Vermont.
#according
Last month, Humana (HUM) announced that it will exit some Medicare Advantage plans for next year, forcing more than half a million seniors to find a new health plan.
The reason for the coverage cutback: high costs and slimmer profit margins in certain markets, according to Humana CFO Celeste Mellet.
It's the second year in a row of plan downsizing for Humana. This year, the company exited three states and 194 counties, affecting around 500,000 members. UnitedHealthcare (UNH) also jettisoned Medicare Advantage plans that served more than 600,000 seniors.
According to KFF research, the percentage of Medicare Advantage enrollees who faced terminated plans this year reached 60% or higher in Wyoming, South Dakota, New Hampshire, North Dakota, and Vermont.
#according
1 month ago
Hotchkis & Wiley, an investment management company, released its second-quarter 2026 investor letter for the "Hotchkis & Wiley Mid-Cap Value Fund." A copy of the letter can be downloaded here. Equity markets posted strong returns in the second quarter of 2026, with the Russell Midcap Index rising 13.8% and the Russell Midcap Value Index returning 13.4%, despite concerns about inflation, a hawkish Federal Reserve, and rising oil prices due to the Iran conflict. Narrow market leadership was evident, particularly semiconductor stocks and other stocks in the AI sector, which saw returns exceeding 100%. The Firm favors quality businesses with attractive valuations, believing that fears regarding AI's impact are overstated. The Hotchkis & Wiley Mid-Cap Value Fund lagged the Russell Midcap Value Index, achieving a 4.74% return in the second quarter, primarily due to underperformance in technology and energy sectors, while stock selection in healthcare contributed positively. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Hotchkis & Wiley Mid-Cap Value Fund highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM), an American insurance company that provides medical and specialty insurance products, delivered strong performance during the quarter. On August 03, 2026, Humana Inc. (NYSE:HUM) closed at $374.50 per share. The one-month return of Humana Inc. (NYSE:HUM) was -5.10%, and its shares gained 47.17% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $44.97 billion.
Hotchkis & Wiley Mid-Cap Value Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Humana Inc. (NYSE:HUM) is one of the largest pure Medicare Advantage (MA) health insurer in the United States. Performance over the quarter was strong following news that the US agreed to increase 2027 payments for private MA plans above its initial proposal earlier in the year. The company's stock has been undervalued due to higher utilization by enrollees and uncertainty regarding reimbursement rates. We view these issues as temporary because the company reprices its business every year, which could lead to a recovery in margins."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#wiley #stocks
In its Q2 2026 investor letter, Hotchkis & Wiley Mid-Cap Value Fund highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM), an American insurance company that provides medical and specialty insurance products, delivered strong performance during the quarter. On August 03, 2026, Humana Inc. (NYSE:HUM) closed at $374.50 per share. The one-month return of Humana Inc. (NYSE:HUM) was -5.10%, and its shares gained 47.17% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $44.97 billion.
Hotchkis & Wiley Mid-Cap Value Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Humana Inc. (NYSE:HUM) is one of the largest pure Medicare Advantage (MA) health insurer in the United States. Performance over the quarter was strong following news that the US agreed to increase 2027 payments for private MA plans above its initial proposal earlier in the year. The company's stock has been undervalued due to higher utilization by enrollees and uncertainty regarding reimbursement rates. We view these issues as temporary because the company reprices its business every year, which could lead to a recovery in margins."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#wiley #stocks
1 month ago
Hotchkis & Wiley, an investment management company, released its second-quarter 2026 investor letter for the "Hotchkis & Wiley Mid-Cap Value Fund." A copy of the letter can be downloaded here. Equity markets posted strong returns in the second quarter of 2026, with the Russell Midcap Index rising 13.8% and the Russell Midcap Value Index returning 13.4%, despite concerns about inflation, a hawkish Federal Reserve, and rising oil prices due to the Iran conflict. Narrow market leadership was evident, particularly semiconductor stocks and other stocks in the AI sector, which saw returns exceeding 100%. The Firm favors quality businesses with attractive valuations, believing that fears regarding AI's impact are overstated. The Hotchkis & Wiley Mid-Cap Value Fund lagged the Russell Midcap Value Index, achieving a 4.74% return in the second quarter, primarily due to underperformance in technology and energy sectors, while stock selection in healthcare contributed positively. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Hotchkis & Wiley Mid-Cap Value Fund highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM), an American insurance company that provides medical and specialty insurance products, delivered strong performance during the quarter. On August 03, 2026, Humana Inc. (NYSE:HUM) closed at $374.50 per share. The one-month return of Humana Inc. (NYSE:HUM) was -5.10%, and its shares gained 47.17% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $44.97 billion.
Hotchkis & Wiley Mid-Cap Value Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Humana Inc. (NYSE:HUM) is one of the largest pure Medicare Advantage (MA) health insurer in the United States. Performance over the quarter was strong following news that the US agreed to increase 2027 payments for private MA plans above its initial proposal earlier in the year. The company's stock has been undervalued due to higher utilization by enrollees and uncertainty regarding reimbursement rates. We view these issues as temporary because the company reprices its business every year, which could lead to a recovery in margins."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#value #quarter #wiley
In its Q2 2026 investor letter, Hotchkis & Wiley Mid-Cap Value Fund highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM), an American insurance company that provides medical and specialty insurance products, delivered strong performance during the quarter. On August 03, 2026, Humana Inc. (NYSE:HUM) closed at $374.50 per share. The one-month return of Humana Inc. (NYSE:HUM) was -5.10%, and its shares gained 47.17% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $44.97 billion.
Hotchkis & Wiley Mid-Cap Value Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2026 investor letter:
"Humana Inc. (NYSE:HUM) is one of the largest pure Medicare Advantage (MA) health insurer in the United States. Performance over the quarter was strong following news that the US agreed to increase 2027 payments for private MA plans above its initial proposal earlier in the year. The company's stock has been undervalued due to higher utilization by enrollees and uncertainty regarding reimbursement rates. We view these issues as temporary because the company reprices its business every year, which could lead to a recovery in margins."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#value #quarter #wiley
2 months ago
July 29 (Reuters) - Humana on Wednesday beat Wall Street estimates for second-quarter earnings as the health insurer's spend on medical services was in line with expectations, but it left its annual adjusted profit forecast unchanged.
Shares of the company were down about 9% in premarket trading.
Humana is one of the largest providers of Medicare Advantage plans serving people aged 65 and older as well as people with disabilities.
Investors have been raising their expectations for insurers, after others including larger peer UnitedHealth raised its outlook and have done a better job at controlling costs.
Once a key source of profit growth for insurers, these privately managed Medicare Advantage plans have come under pressure from rising medical costs for three years as well as tighter reimbursement rates, leading some insurers to scale back or exit underperforming markets.
#humana
Shares of the company were down about 9% in premarket trading.
Humana is one of the largest providers of Medicare Advantage plans serving people aged 65 and older as well as people with disabilities.
Investors have been raising their expectations for insurers, after others including larger peer UnitedHealth raised its outlook and have done a better job at controlling costs.
Once a key source of profit growth for insurers, these privately managed Medicare Advantage plans have come under pressure from rising medical costs for three years as well as tighter reimbursement rates, leading some insurers to scale back or exit underperforming markets.
#humana
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ****** umptions for free cash fl
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ****** umptions for free cash fl
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Gartner, Inc. (NYSE:IT). Established in 1979, Gartner, Inc. (NYSE:IT) is a research and advisory company that provides business and technology insights to help businesses make informed decisions. On July 7, 2026, Gartner, Inc. (NYSE:IT) closed at $140.80 per share. One-month return of Gartner, Inc. (NYSE:IT) was -9.11%, and its shares lost 64.30% over the past 52 weeks. Gartner, Inc. (NYSE:IT) has a market capitalization of $9.43 billion.
Artisan Mid Cap Value Fund stated the following regarding Gartner, Inc. (NYSE:IT) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner, Inc. (NYSE:IT) and Pinterest, each of which dropped by 30% or more during the quarter. Gartner, a technology and business advisory firm, declined following signs of slowing growth and a weaker-than-expected outlook for 2026. Its core research business has been affected by several cyclical headwinds, including US government cost-cutting, uncertainty around trade policy and longer sales cycles. At the same time, some investors have become concerned about the potential long-term impact of artificial intelligence on Gartner's business model. While we take these risks seriously, we believe the company's current challenges are primarily cyclical, and any meaningful disruption from AI is likely to play out over a longer time horizon. Gartner continues to generate strong free cash flow, maintains a solid balance sheet and has been returning capital to shareholders, including approximately $2 billion of share repurchases in 2025. At current levels, we believe the stock appears attractively valued."
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Gartner, Inc. (NYSE:IT). Established in 1979, Gartner, Inc. (NYSE:IT) is a research and advisory company that provides business and technology insights to help businesses make informed decisions. On July 7, 2026, Gartner, Inc. (NYSE:IT) closed at $140.80 per share. One-month return of Gartner, Inc. (NYSE:IT) was -9.11%, and its shares lost 64.30% over the past 52 weeks. Gartner, Inc. (NYSE:IT) has a market capitalization of $9.43 billion.
Artisan Mid Cap Value Fund stated the following regarding Gartner, Inc. (NYSE:IT) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner, Inc. (NYSE:IT) and Pinterest, each of which dropped by 30% or more during the quarter. Gartner, a technology and business advisory firm, declined following signs of slowing growth and a weaker-than-expected outlook for 2026. Its core research business has been affected by several cyclical headwinds, including US government cost-cutting, uncertainty around trade policy and longer sales cycles. At the same time, some investors have become concerned about the potential long-term impact of artificial intelligence on Gartner's business model. While we take these risks seriously, we believe the company's current challenges are primarily cyclical, and any meaningful disruption from AI is likely to play out over a longer time horizon. Gartner continues to generate strong free cash flow, maintains a solid balance sheet and has been returning capital to shareholders, including approximately $2 billion of share repurchases in 2025. At current levels, we believe the stock appears attractively valued."
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Pinterest, Inc. (NYSE:PINS). Pinterest, Inc. (NYSE:PINS) is a social media and visual discovery platform that enables users to find ideas, such as recipes, home, and style inspiration. On July 7, 2026, Pinterest, Inc. (NYSE:PINS) closed at $22.42 per share. One-month return of Pinterest, Inc. (NYSE:PINS) was 2.99%, and its shares lost 37.53% over the past 52 weeks. Pinterest, Inc. (NYSE:PINS) has a market capitalization of $12.56 billion.
Artisan Mid Cap Value Fund stated the following regarding Pinterest, Inc. (NYSE:PINS) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner and Pinterest, Inc. (NYSE:PINS), each of which dropped by 30% or more during the quarter. Pinterest's recent results have been impacted by macroeconomic headwinds, particularly tariffs, which have weighed on advertising spending by large retail customers. Compared with larger social media peers, Pinterest is less diversified and more exposed to consumer-driven categories, making it more sensitive to these pressures. While we continue to view digital advertising as a structurally attractive market with growth likely to exceed that of the broader economy, we chose to exit the position in favor of more compelling opportunities. Nearly four years into the current management team's tenure, progress on key priorities, including user growth, engagement, monetization and profitability, has been slower than expected."
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Pinterest, Inc. (NYSE:PINS). Pinterest, Inc. (NYSE:PINS) is a social media and visual discovery platform that enables users to find ideas, such as recipes, home, and style inspiration. On July 7, 2026, Pinterest, Inc. (NYSE:PINS) closed at $22.42 per share. One-month return of Pinterest, Inc. (NYSE:PINS) was 2.99%, and its shares lost 37.53% over the past 52 weeks. Pinterest, Inc. (NYSE:PINS) has a market capitalization of $12.56 billion.
Artisan Mid Cap Value Fund stated the following regarding Pinterest, Inc. (NYSE:PINS) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner and Pinterest, Inc. (NYSE:PINS), each of which dropped by 30% or more during the quarter. Pinterest's recent results have been impacted by macroeconomic headwinds, particularly tariffs, which have weighed on advertising spending by large retail customers. Compared with larger social media peers, Pinterest is less diversified and more exposed to consumer-driven categories, making it more sensitive to these pressures. While we continue to view digital advertising as a structurally attractive market with growth likely to exceed that of the broader economy, we chose to exit the position in favor of more compelling opportunities. Nearly four years into the current management team's tenure, progress on key priorities, including user growth, engagement, monetization and profitability, has been slower than expected."
2 months ago
Humana Inc. (HUM), headquartered in Louisville, Kentucky, provides medical and specialty insurance products. With a market cap of $47.2 billion, the company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products. The medicare giant is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Wednesday, Jul. 29.
Ahead of the event, ******* ysts expect HUM to report a profit of $6.17 per share on a diluted basis, down 1.6% from $6.27 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
Broadcom's Largest AI Customer Is Fleeing to MediaTek. AVGO Stock Is Still a Buy.
Nasdaq Futures Plunge as Samsung Sparks Chip Selloff
Mark Cuban Asks What If You Didn't Need Health Insurance — And Hospitals Just Treated You, Then Took 10% of Your Pay?
Ahead of the event, ******* ysts expect HUM to report a profit of $6.17 per share on a diluted basis, down 1.6% from $6.27 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
Broadcom's Largest AI Customer Is Fleeing to MediaTek. AVGO Stock Is Still a Buy.
Nasdaq Futures Plunge as Samsung Sparks Chip Selloff
Mark Cuban Asks What If You Didn't Need Health Insurance — And Hospitals Just Treated You, Then Took 10% of Your Pay?
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ******* umptions for free cash f
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On July 7, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $168.72 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 16.69%, and its shares gained 12.08% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $12.92 billion.
Artisan Mid Cap Value Fund stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON Public Limited Company (NASDAQ:ICLR), Humana, Gartner and Pinterest, each of which dropped by 30% or more during the quarter. ICON, a leading provider of outsourced clinical development services to pharmaceutical and biotechnology companies, was the largest detractor. The stock fell sharply—nearly 49% in a single day—after the company announced it would delay its financial results due to an internal review of its accounting, specifically related to revenue recognition in recent years. While ICON indicated its cash position remains intact, the situation raises uncertainty around reported earnings and has pressured investor confidence in the near term. This development comes at a challenging time for the broader contract research industry, where funding constraints and cautious spending by biotech and pharmaceutical companies have already weighed on demand. Although the lack of updated financials limits near term visibility, we believe the stock reflects a more attractive valuation based on conservative ******* umptions for free cash f
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Gartner, Inc. (NYSE:IT). Established in 1979, Gartner, Inc. (NYSE:IT) is a research and advisory company that provides business and technology insights to help businesses make informed decisions. On July 7, 2026, Gartner, Inc. (NYSE:IT) closed at $140.80 per share. One-month return of Gartner, Inc. (NYSE:IT) was -9.11%, and its shares lost 64.30% over the past 52 weeks. Gartner, Inc. (NYSE:IT) has a market capitalization of $9.43 billion.
Artisan Mid Cap Value Fund stated the following regarding Gartner, Inc. (NYSE:IT) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner, Inc. (NYSE:IT) and Pinterest, each of which dropped by 30% or more during the quarter. Gartner, a technology and business advisory firm, declined following signs of slowing growth and a weaker-than-expected outlook for 2026. Its core research business has been affected by several cyclical headwinds, including US government cost-cutting, uncertainty around trade policy and longer sales cycles. At the same time, some investors have become concerned about the potential long-term impact of artificial intelligence on Gartner's business model. While we take these risks seriously, we believe the company's current challenges are primarily cyclical, and any meaningful disruption from AI is likely to play out over a longer time horizon. Gartner continues to generate strong free cash flow, maintains a solid balance sheet and has been returning capital to shareholders, including approximately $2 billion of share repurchases in 2025. At current levels, we believe the stock appears attractively valued."
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Gartner, Inc. (NYSE:IT). Established in 1979, Gartner, Inc. (NYSE:IT) is a research and advisory company that provides business and technology insights to help businesses make informed decisions. On July 7, 2026, Gartner, Inc. (NYSE:IT) closed at $140.80 per share. One-month return of Gartner, Inc. (NYSE:IT) was -9.11%, and its shares lost 64.30% over the past 52 weeks. Gartner, Inc. (NYSE:IT) has a market capitalization of $9.43 billion.
Artisan Mid Cap Value Fund stated the following regarding Gartner, Inc. (NYSE:IT) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner, Inc. (NYSE:IT) and Pinterest, each of which dropped by 30% or more during the quarter. Gartner, a technology and business advisory firm, declined following signs of slowing growth and a weaker-than-expected outlook for 2026. Its core research business has been affected by several cyclical headwinds, including US government cost-cutting, uncertainty around trade policy and longer sales cycles. At the same time, some investors have become concerned about the potential long-term impact of artificial intelligence on Gartner's business model. While we take these risks seriously, we believe the company's current challenges are primarily cyclical, and any meaningful disruption from AI is likely to play out over a longer time horizon. Gartner continues to generate strong free cash flow, maintains a solid balance sheet and has been returning capital to shareholders, including approximately $2 billion of share repurchases in 2025. At current levels, we believe the stock appears attractively valued."
2 months ago
Artisan Partners, an investment management firm, issued its first-quarter 2026 investor letter for the "Artisan Mid Cap Value Fund". A copy of this letter is available for download here. In Q1 2026, the portfolio underperformed the benchmark Russell Midcap Value Index as the market favored momentum-driven stocks over quality factors. Some holdings faced company-specific setbacks and negative sentiment. The Fund's Investor Class: ARTQX returned -4.93%, Advisor Class: APDQX declined by -4.90%, and Institutional Class: APHQX fell by -4.97%, all trailing the Index's 3.68% gain. The equity market in the quarter was mixed, with mid- and small-cap indices showing resilience despite lagging large-cap growth stocks. Volatility increased, initially fueled by interest in AI and private credit, but escalated after the outbreak of war in Iran, leading to rising oil prices. Sector performance varied, with energy leading the gains. The Fund continues to seek companies capable of value growth during market dislocations at attractive entry points. Also, review the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Pinterest, Inc. (NYSE:PINS). Pinterest, Inc. (NYSE:PINS) is a social media and visual discovery platform that enables users to find ideas, such as recipes, home, and style inspiration. On July 7, 2026, Pinterest, Inc. (NYSE:PINS) closed at $22.42 per share. One-month return of Pinterest, Inc. (NYSE:PINS) was 2.99%, and its shares lost 37.53% over the past 52 weeks. Pinterest, Inc. (NYSE:PINS) has a market capitalization of $12.56 billion.
Artisan Mid Cap Value Fund stated the following regarding Pinterest, Inc. (NYSE:PINS) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner and Pinterest, Inc. (NYSE:PINS), each of which dropped by 30% or more during the quarter. Pinterest's recent results have been impacted by macroeconomic headwinds, particularly tariffs, which have weighed on advertising spending by large retail customers. Compared with larger social media peers, Pinterest is less diversified and more exposed to consumer-driven categories, making it more sensitive to these pressures. While we continue to view digital advertising as a structurally attractive market with growth likely to exceed that of the broader economy, we chose to exit the position in favor of more compelling opportunities. Nearly four years into the current management team's tenure, progress on key priorities, including user growth, engagement, monetization and profitability, has been slower than expected."
In its first-quarter 2026 investor letter, Artisan Mid Cap Value Fund highlighted Pinterest, Inc. (NYSE:PINS). Pinterest, Inc. (NYSE:PINS) is a social media and visual discovery platform that enables users to find ideas, such as recipes, home, and style inspiration. On July 7, 2026, Pinterest, Inc. (NYSE:PINS) closed at $22.42 per share. One-month return of Pinterest, Inc. (NYSE:PINS) was 2.99%, and its shares lost 37.53% over the past 52 weeks. Pinterest, Inc. (NYSE:PINS) has a market capitalization of $12.56 billion.
Artisan Mid Cap Value Fund stated the following regarding Pinterest, Inc. (NYSE:PINS) in its Q1 2026 investor letter:
"Among the biggest decliners were ICON, Humana, Gartner and Pinterest, Inc. (NYSE:PINS), each of which dropped by 30% or more during the quarter. Pinterest's recent results have been impacted by macroeconomic headwinds, particularly tariffs, which have weighed on advertising spending by large retail customers. Compared with larger social media peers, Pinterest is less diversified and more exposed to consumer-driven categories, making it more sensitive to these pressures. While we continue to view digital advertising as a structurally attractive market with growth likely to exceed that of the broader economy, we chose to exit the position in favor of more compelling opportunities. Nearly four years into the current management team's tenure, progress on key priorities, including user growth, engagement, monetization and profitability, has been slower than expected."
3 months ago
Pzena Investment Management recently released its first-quarter 2026 commentary for "Pzena Focused Value Strategy." A copy of the letter can be downloaded here. The equity market faced challenges in the first quarter due to the Iran conflict and the related energy price hike, compounded by continued AI-related uncertainty. Despite this volatility, energy stocks led the value index higher, but the portfolio fell short of the index and returned -4.7% (net) vs. 2.1% for the Russell 1000 Value Index. Despite the uncertainty, the firm believes that the current environment presents a strong long-term opportunity. In addition, you can check the Fund's top five holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Pzena Focused Value Strategy highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On June 22, 2026, Humana Inc. (NYSE:HUM) closed at $360.72 per share. One-month return of Humana Inc. (NYSE:HUM) was 19.57%, and its shares gained 51.06% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $43.31 billion.
Pzena Focused Value Strategy stated the following regarding Humana Inc. (NYSE:HUM) in its Q1 2026 investor letter:
"The health care, financials, and technology sectors were the largest detractors from performance during the quarter. Medicare Advantage (MA) insurer Humana Inc. (NYSE:HUM) was the largest individual detractor after CMS (Centers for Medicare and Medicaid Services) proposed a disappointing preliminary MA rate update for 2027. Additionally, management projected rapid growth in its MA membership in 2026, which investors fear may reflect overly rich plan benefit design relative to peers. We view these risks as more timing-related than thesis-changing and added to our position on weakness."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In its first-quarter 2026 investor letter, Pzena Focused Value Strategy highlighted Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On June 22, 2026, Humana Inc. (NYSE:HUM) closed at $360.72 per share. One-month return of Humana Inc. (NYSE:HUM) was 19.57%, and its shares gained 51.06% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $43.31 billion.
Pzena Focused Value Strategy stated the following regarding Humana Inc. (NYSE:HUM) in its Q1 2026 investor letter:
"The health care, financials, and technology sectors were the largest detractors from performance during the quarter. Medicare Advantage (MA) insurer Humana Inc. (NYSE:HUM) was the largest individual detractor after CMS (Centers for Medicare and Medicaid Services) proposed a disappointing preliminary MA rate update for 2027. Additionally, management projected rapid growth in its MA membership in 2026, which investors fear may reflect overly rich plan benefit design relative to peers. We view these risks as more timing-related than thesis-changing and added to our position on weakness."
Humana Inc. (NYSE:HUM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter, up from 53 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
3 months ago
We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Humana Inc. (NYSE:HUM) ranks #9 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller).
Druckenmiller's Stake: $23,842,000
Humana Inc. (NYSE:HUM) is a US health insurer focused mainly on Medicare Advantage plans for seniors. While the stock is up year to date and has also gained over the past year, it is down 28% over the past five years amid profitability pressure in the Medicare Advantage business.
The bull case for the long term is simple: the pressures are cyclical and partially fixable over time. Humana (NYSE:HUM) is targeting a return to at least a 3% Medicare Advantage margin by 2028, suggesting management expects profitability to recover as pricing, benefits, and utilization normalize. The company also expects earnings growth to resume after a 2026 "reset year," where current pressures are absorbed and restructured into new plan designs and pricing.
Membership trends still provide some support, with individual Medicare Advantage membership expected to grow by about 25% over 2026, driven by new sales and improved retention. This shows that despite margin pressure, demand for the product remains strong.
Druckenmiller's Stake: $23,842,000
Humana Inc. (NYSE:HUM) is a US health insurer focused mainly on Medicare Advantage plans for seniors. While the stock is up year to date and has also gained over the past year, it is down 28% over the past five years amid profitability pressure in the Medicare Advantage business.
The bull case for the long term is simple: the pressures are cyclical and partially fixable over time. Humana (NYSE:HUM) is targeting a return to at least a 3% Medicare Advantage margin by 2028, suggesting management expects profitability to recover as pricing, benefits, and utilization normalize. The company also expects earnings growth to resume after a 2026 "reset year," where current pressures are absorbed and restructured into new plan designs and pricing.
Membership trends still provide some support, with individual Medicare Advantage membership expected to grow by about 25% over 2026, driven by new sales and improved retention. This shows that despite margin pressure, demand for the product remains strong.
